title: Effects of epidermal growth factor administration on repair of acetic acid-induced colonic ulcerations in rats.
abstract: The effect of subcutaneous and luminal epidermal growth factor (EGF) administration on acetic acid-induced colonic ulceration was determined in adult rats. Application of acetic acid to the distal colonic lumen caused epithelial denudation, mucosal ulceration and inflammation in the exposed segment. Re-epithelialization was detectable 5 to 7 days later, with near-complete resolution of the lesion by 14 days post-injury. Luminal EGF (1.6 mg/kg bw/day) or subcutaneous EGF (200 micromilligrams/kg bw/day), administered for 4 or 6 days from the time of ulceration failed to enhance re-epithelialization of the acid-exposed segment. However, mucosal and submucosal thickening was attenuated 20-40% by subcutaneous EGF, reflecting a reduction in edema. Luminal EGF had a similar but less substantial effect in the submucosa, but was more effective at attenuating muscularis thickening adjacent to the lesion. In conclusion, administration of exogenous EGF for up to 6 days failed to enhance re-epithelialization of acetic acid-induced colonic ulcerations but did attenuate the associated edematous response.
authors.affiliation: Cooperative Research Centre for Tissue Growth and Repair, Child Health Research Institute, North Adelaide, Australia.
authors.forename: K A
authors.initials: KA
authors.lastname: Ribbons
authors.forename: G S
authors.initials: GS
authors.lastname: Howarth
authors.forename: W D
authors.initials: WD
authors.lastname: Ford
authors.forename: C
authors.initials: C
authors.lastname: George-Nascimento
authors.forename: A J
authors.initials: AJ
authors.lastname: Bourne
authors.forename: L C
authors.initials: LC
authors.lastname: Read
mesh_terms: D019342:Acetic Acid / Q000494:pharmacology; D000818:Animals; D002455:Cell Division / Q000187:drug effects; D003106:Colon / Q000187:drug effects / Q000473:pathology*; D003108:Colonic Diseases / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D004487:Edema / Q000628:therapy; D004815:Epidermal Growth Factor / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D004848:Epithelium / Q000187:drug effects; D006651:Histocytochemistry; D007413:Intestinal Mucosa / Q000187:drug effects / Q000473:pathology; D008297:Male; D018809:Proliferating Cell Nuclear Antigen / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D014456:Ulcer / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology
chemical_list: D018809:Proliferating Cell Nuclear Antigen; D004815:Epidermal Growth Factor; D019342:Acetic Acid